FDA-Approved Anti-Obesity Drugs in the United States

被引:117
作者
Daneschvar, Homayoun L. [1 ]
Aronson, Mark D. [1 ]
Smetana, Gerald W. [1 ]
机构
[1] Harvard Med Sch, Div Gen Med & Primary Care, Beth Israel Deaconess Med Ctr, Shapiro 621C,330 Brookline Ave, Boston, MA 02215 USA
关键词
Anti-obesity drugs; Obesity; Weight loss; Weight loss drugs; PLACEBO-CONTROLLED TRIAL; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE; WEIGHT-LOSS; SMOKING-CESSATION; OBESE ADULTS; DOUBLE-BLIND; OVERWEIGHT ADULTS; SUSTAINED-RELEASE; RANDOMIZED-TRIAL; EATING-DISORDER;
D O I
10.1016/j.amjmed.2016.02.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is a growing health problem in our society and its treatment has been challenging. In recent decades, several anti-obesity drugs have been withdrawn from the market because of reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. The majority of these medications are taken orally, and only one is administered subcutaneously. In this article, we review the efficacy, adverse effects, and mechanism of action of all 5 FDA-approved drugs. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:879.e1 / 879.e6
页数:6
相关论文
共 41 条
  • [1] Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
    Allison, David B.
    Gadde, Kishore M.
    Garvey, William Timothy
    Peterson, Craig A.
    Schwiers, Michael L.
    Najarian, Thomas
    Tam, Peter Y.
    Troupin, Barbara
    Day, Wesley W.
    [J]. OBESITY, 2012, 20 (02) : 330 - 342
  • [2] Antel J, 2012, HDB EXP PHARM, V209, P433, DOI DOI 10.1007/978-3-642-24716-3_
  • [3] A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
    Apovian, Caroline M.
    Aronne, Louis
    Rubino, Domenica
    Still, Christopher
    Wyatt, Holly
    Burns, Colleen
    Kim, Dennis
    Dunayevich, Eduardo
    [J]. OBESITY, 2013, 21 (05) : 935 - 943
  • [4] ASHER WL, 1972, CURR THER RES CLIN E, V14, P525
  • [5] SUDDEN-DEATH ASSOCIATED WITH THYROID-HORMONE ABUSE
    BHASIN, S
    WALLACE, W
    LAWRENCE, JB
    LESCH, M
    [J]. AMERICAN JOURNAL OF MEDICINE, 1981, 71 (05) : 887 - 890
  • [6] BLUNDELL JE, 1977, INT J OBESITY, V1, P15
  • [7] Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling
    Collins, BN
    Wileyto, EP
    Patterson, F
    Rukstalis, M
    Audrain-McGovern, J
    Kaufmann, V
    Pinto, A
    Hawk, L
    Niaura, R
    Epstein, LH
    Lerman, C
    [J]. NICOTINE & TOBACCO RESEARCH, 2004, 6 (01) : 27 - +
  • [8] Valvular heart disease associated with fenfluramine-phentermine
    Connolly, HM
    Crary, JL
    McGoon, MD
    Hensrud, DD
    Edwards, BS
    Edwards, WD
    Schaff, HV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) : 581 - 588
  • [9] Counsel on Pharmacy and Chemistry, 1935, JAMA, V135, P31
  • [10] Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks
    Croft, H
    Houser, TL
    Jamerson, BA
    Leadbetter, R
    Bolden-Watson, C
    Donahue, R
    Metz, A
    [J]. CLINICAL THERAPEUTICS, 2002, 24 (04) : 662 - 672